Northern Trust
PMCB icon

Northern Trust’s PharmaCyte Biotech PMCB Stock Holding History

Northern Trust’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.1K Sell
32,624
-2,977
-8% -$2.24K ﹤0.01% 4351
2026
Q1 		$23.7K Hold
35,601
– – ﹤0.01% 4321
2025
Q4 		$25.8K Buy
35,601
+16,393
+85% +$14.8K ﹤0.01% 4367
2025
Q3 		$18.6K Hold
19,208
– – ﹤0.01% 4381
2025
Q2 		$20.9K Hold
19,208
– – ﹤0.01% 4330
2025
Q1 		$24K Hold
19,208
– – ﹤0.01% 4322
2024
Q4 		$30.2K Hold
19,208
– – ﹤0.01% 4334
2024
Q3 		$36.7K Hold
19,208
– – ﹤0.01% 4259
2024
Q2 		$37.6K Sell
19,208
-21
-0.1% -$45 ﹤0.01% 4248
2024
Q1 		$45.6K Sell
19,229
-54
-0.3% -$117 ﹤0.01% 4238
2023
Q4 		$41.7K Hold
19,283
– – ﹤0.01% 4264
2023
Q3 		$40.5K Sell
19,283
-9,132
-32% -$23.3K ﹤0.01% 4218
2023
Q2 		$81.3K Sell
28,415
-833
-3% -$2.5K ﹤0.01% 4089
2023
Q1 		$85.1K Sell
29,248
-8,371
-22% -$24.6K ﹤0.01% 4117
2022
Q4 		$110K Sell
37,619
-11
-0% -$32 ﹤0.01% 4063
2022
Q3 		$90K Hold
37,630
– – ﹤0.01% 4145
2022
Q2 		$84K Buy
37,630
+1,989
+6% +$4.35K ﹤0.01% 4239
2022
Q1 		$82K Buy
35,641
+185
+0.5% +$411 ﹤0.01% 4411
2021
Q4 		$89K Buy
+35,456
New +$97.7K ﹤0.01% 4457

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Northern Trust's PMCB Position: Q2 2026 in Review

Northern Trust reduced its PharmaCyte Biotech (PMCB) stake by 8.4% in Q2 2026, selling an estimated $2.24K and leaving 32,624 shares worth $25.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4351.

Northern Trust first reported a position in PMCB in Q4 2021 and has held it in 19 quarters since. The position peaked at $110K in Q4 2022. 19 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Northern Trust held 32,624 shares of PharmaCyte Biotech worth $25.1K as of Q2 2026.
  • Northern Trust sold 2,977 PharmaCyte Biotech shares in Q2 2026, an estimated $2.24K.
  • PharmaCyte Biotech made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4351 holding.
  • Northern Trust first reported a position in PharmaCyte Biotech in Q4 2021 and has held it in 19 quarters since.
  • Northern Trust's PharmaCyte Biotech position peaked at $110K in Q4 2022.
  • 19 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.